
Conformis received FDA 510(k) clearance to market the Cordera™ Hip System.
Cordera is an uncemented hip replacement comprising femoral and acetabular components. It can be used with or without a pre-operative CT scan to design Conformis iJigs® and a personalized surgical plan. All components are delivered sterile to hospitals and ambulatory surgery centers.
Cordera is indicated for use in total and revision hip replacement.
“Our new Cordera™ Hip System is the first expansion of our growing total hip portfolio. The system, which is inserted using an anterior or posterior surgical approach, will allow surgeons to treat a wider range of patients effectively,” said Mark Augusti, President and CEO. “And surgeons have the option to select an accompanying personalized surgical plan and best in class PSI guides provided through a safe, sterile, and efficient model for hospitals and ambulatory surgery center sites of care.”
The first product in Conformis’ hip line launched commercially in November 2019 and provided a patient-specific stem.
Conformis received FDA 510(k) clearance to market the Cordera™ Hip System.
Cordera is an uncemented hip replacement comprising femoral and acetabular components. It can be used with or without a pre-operative CT scan to design Conformis iJigs® and a personalized surgical plan. All components are delivered sterile to hospitals and...
Conformis received FDA 510(k) clearance to market the Cordera™ Hip System.
Cordera is an uncemented hip replacement comprising femoral and acetabular components. It can be used with or without a pre-operative CT scan to design Conformis iJigs® and a personalized surgical plan. All components are delivered sterile to hospitals and ambulatory surgery centers.
Cordera is indicated for use in total and revision hip replacement.
“Our new Cordera™ Hip System is the first expansion of our growing total hip portfolio. The system, which is inserted using an anterior or posterior surgical approach, will allow surgeons to treat a wider range of patients effectively,” said Mark Augusti, President and CEO. “And surgeons have the option to select an accompanying personalized surgical plan and best in class PSI guides provided through a safe, sterile, and efficient model for hospitals and ambulatory surgery center sites of care.”
The first product in Conformis’ hip line launched commercially in November 2019 and provided a patient-specific stem.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.